In his talk, Dr. Ernst Hafen turned to the question of how cell, organ, and body size is genetically controlled. He explained that understanding the mecha nisms that control organismal size is of fundamental biological and clinical importance. By per forming genetic screens that Abstract Last October, the 7th meeting of the Global Arthritis Research Network was held in Zurich, Switzerland. European and American experts who have made major recent contributions to molecular biology got together to provide insights into novel technologies and approaches useful for biomedical research, especially for research on arthritis and related conditions.
Introduction
Th e purpose of Global Arthritis Research Network (GARN) is to promote and encourage scientifi c interactions and collaborations that facilitate the progress of basic and clinical research in arthritis and related conditions. Last October, the 7th meeting of GARN was held in Zurich, Switzerland. Th e program -organized by Steff en Gay and Peter E Lipsky, associate editor and editor-in-chief, respectively, of Arthritis Research & Th erapy -was designed to provide the attendees with the newest insights into molecular biology related to musculo skeletal diseases. Th e opening session, entitled 'Genetics -epigenetics -proteomics' , was followed by sessions on 'Signaling pathways' , 'Molecular immunology' , 'Cellular autoimmunity' , and 'Cell biology' . Th e fi nal session, on 'Updates in rheumatology' , ended with an outlook on novel modulators of pain. During the breaks and social gatherings, students and young fellows had the opportunity to ask questions and discuss the novel aspects of advanced technologies in molecular research. Fellows from the Center of Experimental Rheumatology at the Department of Rheumatology at the University Hospital in Zurich prepared notes from each session. Dr. Ioannis Ragoussis's presentation focused on novel genotyping technologies for the identifi cation of diseaseassociated changes in DNA sequences. He began his talk by giving an overview of the role of single nucleotide polymor ph isms in human diseases and the currently available DNA sequencing platforms. Since the analysis of a larger number of patients is hindered by limitations of currently available technologies, Dr. Ragoussis presented a new sequencing platform. Th is novel genotyping tech nology is based on an Aff ymetrix genotyping array (Aff ymetrix, Santa Clara, CA, USA) combined with DNA ligation steps allowing the sequencing of a large number of samples. To illustrate this improved sequencing method, Dr. Ragoussis presented data from his lab, showing newly identifi ed copy number variation events in patients with autism. In the last part of his talk, he discussed the interesting fi eld of transcriptome analysis. He explained that RNA quantifi cation by sequencing combined with chromatin immunoprecipitation off ers a powerful new tool for studying the regulation of gene expression. He also mentioned how microRNA (miRNA) quantifi cation studies followed by RNA transcriptome analysis (miRNA-RNA Seq) could be used to understand the widespread eff ect of miRNAs on the RNA transcriptome.
allow a randomized intro duction of mutations into the genome of Drosophila melanogaster, his lab was able to identify novel genes associated with body size. In summary, the investigators found approximately 60 genes that promoted or inhibited growth. Th e majority of these genes encode proteins that are part of the insulin/TOR signaling pathway. Further more, they could show that the activity of this pathway infl uences the cellular and organismal growth of Droso phila fl ies. In future projects, his group will perform large proteomic approaches to further characterize the function of these genes associated with body size. In the last part of his talk, Dr. Hafen discussed the infl uence of environmental conditions on growth and survival. He illustrated the role of the tumor suppressor Pten in caloric restriction (CR) . Th e reduction of Pten activity, as he explained, is suffi cient to compensate impaired insulin signaling and thus represents a growth advantage under starvation. To understand the complex role of Pten activity in organismal growth, his lab will employ a combi nation of single-gene analysis with quantitative measurement of protein levels (mass spectrometry).
Functional analysis of mammalian genomes Joel Schick, Munich, Germany
Dr. Joel Schick began his presentation with the statement that human and mouse genomes are highly conserved and comprise approximately 20,000 coding genes. Th is high degree of similarity between the human and murine genomes can be used to study human diseases in mice. In this regard, the detailed characterization of each murine gene and its function is essential. A powerful tool for studying gene function is the specifi c silencing of genes (knockout) by applying conditional gene-trapping and gene-targeting methods. Th e goal of Dr. Schick's group and their partners (in the European Conditional Mouse Mutagenesis Program) is to generate a collection of up to 13,000 mutated genes in mouse embryonic stem cells. Th is library will enable mouse mutants to be established worldwide in a standardized and cost-eff ective manner, making mouse mutants available to a much wider biomedical research community. In his talk, Dr. Schick explained diff erent methods for knocking out gene expression in mouse embryonic cells. For instance, he mentioned gene trap vectors, a class of promoter-less reporter gene cassettes that integrate randomly into a large collection of chromosomal sites. It has been shown that gene trap mutagenesis is the method of choice for large-scale, genome-wide mutagenesis. Furthermore, Dr. Schick illustrated the use of the so-called Cre-Lox recombi nation system to generate a conditional knockout animal; in this system, a gene is knocked out only in a specifi c tissue or at a specifi c time. Cre-Lox recom bination involves the targeting of a specifi c sequence of DNA and splicing it with the help of an enzyme called Cre recombinase. At the end of his talk, Dr. Schick mentioned established repositories for the collection and distribution of relevant mutant strains essential for basic biomedical research. Are prions and prionoids a more common underlying principle of human diseases than appreciated until now? In the fi rst part of his presentation, Adriano Aguzzi raised the question of whether not only the 'bona fi de' prion disease caused by the prion particle PrP Sc but also other disorders such as Alzheimer's disease or AA amyloi dosis should be considered prion diseases. Th e pathobiological background of this view is the following: a protein can exist in two states: the normal state and the misfolded prion state. A pathogenic event initiates an assembly of misfolded proteins into aggregates, thus leading to the progressive neurologic degeneration seen in patients. PrP
Sc is transmissible and follows an infectious life cycle; that is, it acts as a seed to recruit more PrP
Sc . Diseases such as Alzheimer's disease or AA amyloidosis have a similar pathogenesis and are caused by the deposition of misfolded proteins (amyloid-β and amyloid A, respectively). Aguzzi attested that AA amyloidosis has the 'best chances' of becoming a prion disease. He pointed out that prions may even have conserved 'good' properties that may be the reason that prion formation was not simply eliminated by evolution. In the second part of the presentation, Aguzzi concentrated on his own group's recent work, which deals with the question of how to study the neurotoxicity of PrP Sc . Th ey developed an ex vivo assay using mouse cerebrellar slices that could be cultured for several weeks and infected with prions. In the slices, as in the living animal, prion infection induced neurodegeneration. Th is technique allows investigators to address neurotoxicity questions that are diffi cult to study in vivo. With this model, diff erent substances were tested for their neuroprotective activity, and work on how prion degradation could be infl uenced is ongoing.
Novel targeting with DARPins Andreas Plückthun, Zurich, Switzerland
Andreas Plückthun started his presentation with the question ' Antibodies in infl ammatory diseases: is it all done?' -to which he answered 'no' , pointing out that approxi mately 30% of the patients do not respond to antitumor necrosis factor (anti-TNF) treatment. Further more, opportunistic infections and enormous costs are common problems of biological treatments of today. After providing a short historical overview ranging from the fi rst monoclonal antibodies to recombinant antibodies and synthetic antibodies, he concentrated on a class of molecules -called DARPins (designed ankyrin repeat proteins) -that may substitute antibodies. Th ese molecules are assembled from a variable number of ankyrin repeat domains that contain several randomized positions, making it possible to generate libraries of DARPins with a multitude of diff erent binding surfaces. Th eir unique properties -namely these molecules are extremely well expressed, soluble, stable, and nonaggregating -and the possibility of carrying out the whole selection process in vitro by ribosomal display make them highly interesting for therapeutic approaches and research. Discussing the potential use of DARPins in therapy, Plückthun summarized work done to achieve high stability, affi nity, and the ability to penetrate cells. Furthermore, he introduced a new concept of targeted gene therapy which is in development at the moment. In this therapy, adenoviruses carrying the therapeutic nucleic acid 'fi nd' their particular target cells with the help of a specifi cally selected DARPin adapter. Finally, coming to applications in research, he pointed out the limitations of using DARPins in proteomics and systems biology and briefl y introduced a new approach for designing modular peptide-binding scaff olds with the vision of achieving peptide recognition with predesigned building blocks of engineered Armadillo repeat proteins.
Modifi cation of histones Udo Oppermann, Oxford, UK
To begin with, Udo Oppermann gave some background information on nucleosome structure and histone modifi cations and their relevance to the immune system. He continued with the presentation of the Structural Genomics Consortium (SGC), a public-private partnership that aims to place protein structures of relevance to human health into the public domain and thus to promote drug discovery. Based on the SGC, the Chemical Probe Consortium works on the development of probes against specifi c biological targets which are then made available to the public. To concentrate on some of the possible 400 epigenetic targets, they chose bromo and tudor domains, which 'read' acetyl and methyl marks, respectively, and lysine demethylases. He presented recent progress on two targets in particular. One work was concerned with the development of a small-molecule competitor of the bromodomain BRD4, which is of interest for immunologic research since it binds to acety lated nuclear factor-kappa-B (NF-κB) and thus functions as a coactivator. Th e second work dealt with the search for small-molecule inhibitors of Jumonji proteins (lysine demethylases for histones and other non-histone proteins). For this, they started from α-ketoglutarate, a cosubstrate for the demethylation process. In the end, they came up with a specifi c inhibitor of Jmjd3, a lysine demethylase that has already been implicated in immunerelated processes. Oppermann stated the prospect that the molecule would be publicly available in the future as soon as it has been validated in a cell-based system.
DNA methylation alterations and autoimmune diseases
Esteban Ballestar, Barcelona, Spain DNA methylation is the most common epigenetic modifi cation and involves the 5'-methylation of cytosine in CG dinucleotides that usually reside in so-called CpG islands. Esteban Ballestar spoke about aberrant DNA methylation found in diseases ranging from cancer to genetic defects concerning epigenetic factors (for example, Rett syndrome or ICF [immunodefi ciency, centromeric region instability, and facial anomalies] syndrome) and imprinting disorders such as Angelman and Prader-Willi syndromes. He pointed out that under normal condi tions DNA methylation plays an important role in X chromosome inactivation, imprinting, and the regulation of tissue-specifi c gene expression. Th erefore, promoter CpG islands tend to be demethylated whereas DNA repeat regions are normally methylated. In the diseased state, this seems to be reversed to a certain degree. Although cancer cells show a global hypomethylation, specifi c gene promoters, mainly those of tumor suppres sor and DNA repair genes, show a local hypermethylation that leads to the silencing of these genes. Ballestar concluded that, also in autoimmune diseases, epigenetic infl uences are indicated. Having a special interest in epigenetic diff erences between monozygotic (MZ) twins, in whom global epigenetic diff erences were shown to accumulate with age, his group generated DNA methy lation profi les of MZ twins discordant for autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and dermatomyositis. Signifi cant diff erences could be detected only for SLE discor dance, and many of the aff ected genes had an immuno logic function and were of relevance in lupus patho genesis. Hypomethylation of several genes was validated by bisulfi te pyrosequencing (for example, IFNGR2 and MMP14). In contrast, DNA methylation of repetitive sequences such as LINE1 or Alu repeats was not aff ected. Finally, he put forward the idea that there may be an active demethylation of pathogenetically relevant genes in lupus. In the end, Ballestar presented a second study demonstrating an association between Epstein-Barr virus infection and DNA methylation in B cells.
Session 2: Signaling pathways
Chairs: Joachim Kalden, Erlangen, Germany, and Gyorgy Nagy, Budapest, Hungary
Session 2 summarized by Maria Filkova
The infl ammasome Jürg Tschopp, Epalinges, Switzerland
At the beginning of his talk, Dr. Tschopp introduced the infl ammasomes as cytosolic multiprotein complexes that can proteolytically activate caspase-1 and this subsequently leads to maturation and secretion of active interleukin IL-1β and IL-18. Th e innate immune system is characterized by its ability to recognize a wide range of pathogen-associated molecular patterns (PAMPs) (such as fungi, protozoa, bacteria, or viruses) and sterile danger-associated molecular patterns (DAMPS) (such as DNA, ATP, crystals, asbestos, β amyloid, and choles terol). PAMPs are recognized by pattern-recognition receptors that include the Toll-like receptors, NOD-like receptors (NLRs), C-type lectin receptors, and several other receptors. However, NLR proteins can also detect DAMPs and their recognition leads to the activation of the infl am masome. NLR-related pathways (NALP or NLRP, IPAF, and AIM2) are associated with chronic non-infectious infl am matory diseases. Dr. Tschopp presented the role of the infl ammasome in the pathogenesis of several chronic infl ammatory conditions.
Gout is associated with the deposition of monosodium urate (MSU) crystals. It was shown that molecular mecha nisms underlying the infl ammation initiated by MSU activate the NALP3 infl ammasome. Th e involvement of IL-1β in this infl ammatory cascade might explain the success of IL-1ra, IL-1Trap, and IL-1β antibody treatment in gout infl ammation.
NALP3 infl ammasome is implicated in the pathogenesis of another chronic infl ammatory state: type 2 diabetes mellitus (DMT2). Reactive oxygen species (ROS) generation is necessary for NALP3 activation in DMT2. Moreover, when intracellular ROS increases, thioredoxininteracting protein (TXNIP) is released from the thioredoxin complex. Th e oxidoreductase thioredoxin is then able to act as an ROS scavenger and then free TXNIP interacts with NALP3. Th us, TXNIP is a ligand for NLRP3, leading to elevated IL-1β production. IL-1β has a pathogenic role in islet dysfunction and is a risk factor for the development of DMT2 in humans. Mouse models and human clinical trials suggest that IL-1β antagonism may be a promising treatment for DMT2. Finally, Dr. Tschopp presented an interesting eff ect of interferon-beta (IFN-β) on inhibition of NALP3 signaling in multiple sclerosis.
Cofactor-specifi c regulation of NF-κB-dependent gene expression Michael Hottiger, Zurich, Switzerland
Dr. Hottiger discussed mechanisms underlying NF-κB activity and emphasized the eff ect of cofactors on regulation of NF-κB-dependent gene expression. Th e NF-κB family consists of fi ve complexes that have an important function in regulating immune and infl ammatory responses, apoptosis, cell proliferation, diff erentiation, and tumorigenesis. NF-κB-specifi c activity depends on the preferential recruitment and localization of NF-κB homodimers/heterodimers, on the interaction with chromatin that enables its either constitutive and immediate or regulated and late accessibility, and on the combination of cofactors and post-translational modifi cation of NF-κB dimers.
Dr. Hottiger showed that the p65 subunit of NF-κB is acetylated in vitro and in vivo at three diff erent lysines -K310, K314, and K315 -by the histone acetyltransferase p300. Although general transcriptional activity of RelA/ p65 was not aff ected, there are specifi c sets of genes that were upregulated or downregulated by lysine-specifi c RelA/p65 acetylation. SIRT-2 interacts with p65 in cytoplasm and contributes to NF-κB-dependent gene expression via deacetylation of lysine K310. Poly (ADP-ribose) poly merase-1 (PARP-1) can also act as a promoterspecifi c coactivator of NF-κB. Th e eff ect of PARP-1 is indepen dent of its enzymatic activity but its direct interaction with both subunits of NF-κB is required for its co activator function. Moreover, it was shown that acety lation of PARP-1 at specifi c lysine residues mediated by p300/CREB-binding protein is necessary for the above mentioned interaction of PARP-1 with NF-κB and coactivation of NF-κB by p300. CARM1 (coactivatorasso ciated arginine methyltransferase) is another transcrip tional coactivator of NF-κB. CARM1 forms a complex with p300 and NF-κB (interacts directly with the NF-κB subunit p65) and thus, together with the transcriptional coactivators p300/CREB-binding protein, regu lates a subset of NF-κB-dependent genes. PRMT1 (protein arginine methyltransferase 1) synergistically coactivates NF-κB-dependent gene expression in a complex with the transcriptional coactivators p300/CREB-binding protein, CARM1, and PARP1. In the fi nal part of the talk, Dr. Hottiger presented the data on a mouse model of enterocolitis induced by Salmonella typhimurium and showed that PARP1 is expressed in the proliferative zone of cecum crypts, where it is required for the effi cient expression of proinfl ammatory genes. In conclusion, cooperation between cofactors p300, PARP1, CARM1, and PRMT1 regulates NF-κB-dependent gene activation in vivo.
Modulation of the immune response by exosomes Paul Robbins, Pittsburgh, PA, USA
In the introduction to his talk, Dr. Robbins described exosomes as nanovesicles (40 to 100 nm) generated by diff erent cell types: reticulocytes, immune cells, platelets, epithelial cells, tumor cells, and so on. Exosomes contain antigen-presenting molecules MHC (major histo compati bility complex) I and MHC II and adhesion, regulatory, and costimulatory molecules and nucleic acids, including miRNAs.
Dr. Robbins demonstrated that exosomes derived from dendritic cells (DCs) treated with immunomodulatory cytokines (IL-10 and IL-4) inhibit infl ammation in a murine model of delayed-type hypersensitivity (DTH). Moreover, systemic administration of exosomes derived from IL-10-treated DCs is able to suppress the onset of murine collagen-induced arthritis (CIA) as well as to reduce the severity of established arthritis.
Th e ability of the modifi ed DCs expressing IL-4 and exosomes derived from these DCs to suppress the DTH response is MHC class II-and Fas-ligand/Fas-dependent. Costimulatory molecules, such as B7-1/2 and PD-L1/2, play an important role in the function of antigen-presenting cells (APCs). Lack of B7-1 or B7-2 on DCs results in a loss of the ability of IL-10-treated DCs and their exosomes to suppress the DTH response, whereas IL-10-treated DCs expressing no PD-L1/2, as well as their secreted exosomes, have no ability to suppress DTH responses. Th us, B7-1 and B7-2, but not PD-L1 and PD-L2, on IL-10-treated DCs and derived exosomes are required for immunosuppressive functions of both DCs and exosomes.
As mentioned above, exosomes released by APCs express MHC, adhesion, and costimulatory molecules and may function as antigen-presenting particles. It was presented that exosomes fi rst bind to the APC surface and then are internalized by DCs. Th us, these internalized exosomes can be subsequently processed by DCs for presentation to T cells. Dr. Robbins showed that exosomes derived directly from plasma are immunosuppressive. Th e anti-infl ammatory eff ect of plasmaderived exosomes in immunized mice was mediated by exosomes containing MHC II, FasL, and CD11b. Moreover, TNFα was shown to be bound on the membrane of exosomes derived from mouse models of CIA and from plasma of patients with RA. Th erefore, there is a question of exosomes as a biomarker of the disease.
In conclusion, the immunosuppressive eff ect of exosomes is dependent on the presence of MHC II, FasL, and B7-1 and B7-2, and exosomes may be internalized by APCs. Th us, APC-derived exosomes could be used therapeutically for the treatment of autoimmune disease and infl ammatory disorders. However, further experiments are needed to elucidate in detail the structure, mechanism of action, and clinical application of exosomes. Lanzavecchia started his presentation by describing the role of Th -17 cells in inducing experimental autoimmune encephalomyelitis (EAE). He showed that mice lacking CCR6, a chemokine receptor characteristic of Th -17 cells, are resistant to the induction of EAE. CCR6 binds to its ligand, CCL20, in choroid plexus and controls immune surveillance of the central nervous system. Next, he discussed the diff erentiation of Th -17 cells in humans and mice. In mice, the diff erentiation of Th -17 cells requires transforming growth factor-beta (TGF-β) and IL-6, where as in humans IL-1β and IL-6 are needed. In humans, in contrast to mice, TGF-β has inhibitory eff ects on Th -17 diff erentiation. Lanzavecchia explained that in mice IL-22 has been considered a typical Th -17 cytokine and is made by fully diff erentiated Th -17 cells. It has been linked to skin homeostasis and infl ammation. Of interest, in humans, most of the IL-22-producing cells do not make IL-17. Th e diff erentiation of T cells producing only IL-22 is effi ciently induced in naive T cells by plasma cytoid DCs in an IL-6-and TNF-dependent way. Lanza vec chia and colleagues are developing high-throughput methods to analyze the human memory responses. Th e idea is that analyzing the repertoire of B cells, plasma cells, and memory T cells may allow us to isolate mono clonal antibodies and T-cell clones to identify target antigens and the specifi c class of response. Finally, he showed that Candida albicans and Staphylococcus aureus both induce Th -17 diff erentiation, but in diff erent ways. C. albicans induces Th -17 diff erentiation in an IL-1β-dependent way. IL-1β shuts off IL-10 production, so cells make IL-17 but not IL-10. In contrast, S. aureus can induce Th -17 diff erentiation in an IL-1β-independent manner. In this case, IL-10 production is retained, so these cells have less potential to induce infl ammation.
Break of immunotolerance Iain McInnes, Glasgow, UK
McInnes started his talk by addressing the importance of adaptive immunity in the pathogenesis of RA. He explained how diffi cult it is to observe the breach of endogenous tolerance in an animal model, because these models rely on aggressive and artifi cial self-antigen immuni zation and this does not allow us to assess the very early breach of immunotolerance. A new approach is to look at DC behavior and their phenotype in RA, and the idea is to set up an in vivo model system that can be analyzed in real time. McInnes and colleagues took DCs and loaded them up with selected antigens (collagen type II whole protein) to generate a collageninduced mouse model of arthritis. By analyzing the interactions between DCs and T cells in this in vivo model, they could demon strate conventional DC (cDC) activation and antigen presentation associated with breach of self-tolerance, an ability of these cells to transfer autoimmunity, together with a central role for cDCs in the TNFα-dependent development of selfreactivity and RA pathogenesis. Furthermore, he showed some data on the eff ect of abatacept to limit the breach of self-tolerance via eff ects on the generation of T follicular helper cells. Abatacept prevented the emergence of self-reactivity and has potential usefulness in early infl ammatory arthropathies associated with autoantibody expression.
The tumoricidal activity of interleukin-12 is mediated via lymphoid tissue-inducer cells Burkhard Becher, Zurich, Switzerland
In a wonderful talk, Becher presented his data on IL-12-mediated repression of subcutaneous melanoma. Th ere are many cytokines used in cancer immunotherapy, such as IFN-α, IL-2, and IL-12. To determine the mechanisms by which IL-12 mobilizes antitumor immunity, Becher and his group generated B16.F10 mouse melanoma cell lines that continuously release a fusion protein of IL-12. Th ey could show that IL-12 signifi cantly reduced tumor growth in wild-type mice whereas in IL12rb2 −/− mice, which lack the IL-12-specifi c receptor subunit, melanoma cells showed no reduction in growth. But how does IL-12 repress cancer? To answer this question, they did a systemic analysis of the IL-12-induced immune responses and demonstrated that tumoricidal activity of IL-12 is independent of adaptive immunity, lymphocytes, or circulating natural killer cells. By excluding a series of cell types, which were candidates for IL-12-mediated anti tumor response, they observed that IL-12-responsive tumor-invading cells are in fact an innate, lineage-negative leukocyte belonging to a subset of lymphoid tissue-inducer (LTi) cells expressing the natural cyto toxicity receptor NKp46. Th ese LTi cells also produce IL-22 and IL-17, but of interest, the IL-12-mediated melanoma repression seemed to be independent of these eff ector cytokines. IL-12-stimulated NKp46 + LTi cells alter tumor microvasculature and this leads to up regulation of adhesion molecules (such as vascular cell adhesion molecule) and subsequent tumor control. Further more, IL-33 improves the neutrophil migration on the site of infection and prevents downregulation of CXCR2 in neutrophils during sepsis. IL-33 allows the persistent expression of CXCR2 in neutrophils by blocking the activity of GSK2. Dr. Liew claimed that IL-33 is important in human sepsis. IL-33 induces the migration of human neutrophils during infl ammation. Interestingly, sepsis non-survivors have less CXCR2 in their peripheral blood neutrophils than sepsis survivors. Finally, he showed that the soluble ST2 is highly expressed in the serum of non-survivors of sepsis. His talk concluded on the role of IL-33 osteoclast diff erentiation. IL-33 is expressed in the joints of TNFα transgenic mice. IL-33 reduces bone erosion and osteoclast formation in TNFα transgenic mice. Th e expression of TRAP, NFAT, and cathepsin K is reduced after IL-33 treatment. ST2 knockout mice have more bone erosion than wild-type mice. In addition, IL-33 increases the number of macrophages, DCs, and neutrophils in the spleen of the mice. Interestingly, IL-33 inhibits osteoclast diff erentiation and promotes the development of MT2 macrophages.
Session 4: Cellular autoimmunity

Genome-wide association studies for rheumatoid arthritis Lars Klareskog, Stockholm, Sweden
Dr. Klareskog analyzed the diff erent genetic and environmental interactions of antibodies to citrullinated protein antigen (ANCA)-positive individuals as a risk factor for RA. Diff erent studies in RA have shown that there is a genetic risk for RA. Th e most important susceptibility genes are PTPN2 and HLADR shared epitope (SE). New genome-wide genetic studies have shown that HLADR SE and PTPN2 are more frequent in ANCA-positive cases than ANCA-negative RA cases. Dr. Klareskog emphasized that environmental exposure such as smoking can have a great impact on the genetic infl uence of RA. Environmental-gene interaction studies have shown that there is a great risk of RA if you are a smoker and HLADR SE-positive. Other studies have analyzed geneto-gene interaction. Th ese studies have determined that the PTPN2 susceptibility gene, together with HLADR SE and smoking, increases the risk for RA. Dr. Klareskog created a model for smoking and HLADR SE genes which could be tested in the laboratory. Chronic exposure of lungs to smoking increases the activation of the peptidylarginine deiminase enzymes that cause the citrullination of diff erent proteins in the lung. APCs (macrophages and DCs) that have the SE motif may bind to some of these citrullinated proteins and trigger an immune response. Activated T cells are generated and interact with B cells. In turn, the activated B cells produce ANCA antibodies that are present very early in RA. Synovial infl ammation in the joint can citrullinate synovial antigens that form complexes with ANCA and bind to the Fc receptors of synovial macro phages. His talk concluded that geneticists should separate patients with RA into two diff erent subsets and functional immune system studies should be performed in specifi c T-cell subsets with a specifi c genetic and environmental background. Th omas Pap started the cell biology session by introducing the aggressive phenotype of RA synovial fi broblasts (SFs). In an in vivo experiment, RA SFs, together with human cartilage, were implanted into severe combined immunodefi cient (SCID) mice. RA SFs showed an active movement to the naive cartilage, leading to a marked destruction of the cartilage. Interestingly, RA SFs, but not osteoarthritis (OA) SFs, were able to spread the disease in the SCID mice model. Next, he discussed inducible human tumor necrosis factor transgenic (hTNFtg) mice. Like the constitutive TNF transgenic mice, these mice show an RA-like arthritis, but allow the analysis of genes, the knockout of which is embryonically lethal in a TNFα infl ammatory background. By using these mice, Th omas Pap's group wanted to address the question of whether pathogenic changes in RA are triggered and maintained by cartilage damage. Th ey observed that the loss of proteoglycans is an important prerequisite for the attachment of SFs to cartilage in hTNFtg mice. Th is attachment was mediated by integrins, as confi rmed by the fact that loss of α 1 β 2 integrin reduced cartilage destruc tion not only in vitro but also in hTNFtg mice. In addition, the loss of other proteoglycan-sensing mole cules, such as syndecan 4, protected mice from cartilage damage in the hTNFtg mice model of RA. Furthermore, this protection was linked to reduced production of matrix-metalloproteinase 3. Pap and his group observed the upregulation of syndecan 4 in RA SFs and in hTNFtg mice and hypothesized that syndecan 4 not only is required for SF attachment but also modulates cytokine signaling in SFs by binding the key RA cytokine IL-1.
Dynamic regulation of chemokines and their receptors
Molecular biology of aging Trygve Tollefsbol, Birmingham, AL, USA
In his talk, Tollefsbol pointed out the trade-off between a person's dream to stay young and the continuous need for CR. Nowadays, the intake of 25% to 40% less calories, including all needed nutrients, was shown to be the best way to stay young, as CR promoted longevity not only in yeasts and mice but also in non-human primates. Th is fi nding was nicely illustrated by pictures from calorie-restricted, young-looking (but incredible hungry) primates.
Tollefsbol connected this eff ect with the molecular clock of aging. Telomere shortening was shown to correlate with the age of a cell. Moreover, telomerase was found to be activated in cancer cells. Th e group of Tollefsbol wondered whether in vitro sugar reduction could help answer questions about human CR and aging. Indeed, glucose restriction extended the lifespan in a human embryonic fi broblast cell line (WI-38) and, moreover, induced apoptosis in a precancerous human cell line (WI-38/S). Levels of hTERT, the gene for telomerase reverse transcriptase, were found to be induced and the tumor-suppressor protein p16 to be reduced after 2 to 4 weeks of glucose restriction in the normal cell line (WI-38). In the precancerous cell line (WI-38/S) the eff ects were the reverse and lower levels of hTERT and higher levels of p16 were detected. Furthermore, glucose restriction was shown to result in chromatin remodeling of the promoters of the hTERT and p16 genes. In conclusion, this presentation clearly showed that glucose restriction mediates its eff ects by epigenetic regulation via hTERT and p16, thereby extending the cellular lifespan of normal cells or mediating cellular senescence by induction of apoptosis in precancerous cells.
Tissue repair with stem cells
Rocky S Tuan, Pittsburgh, PA, USA Tuan started his presentation by listing diff erent treatment options for degenerative joint diseases, such as total joint arthroplasty, non-steroidal anti-infl ammatory drugs, chondrocyte implantation, and cartilage transplantation, and fi nally put an emphasis on regenerative surgery methods. Tuan wanted to apply principles of engineering and life sciences to the regeneration of tissue and cell organs. To address this topic, he worked with human mesenchymal stem cells (hMSCs). Th ese cells were shown to form cartilage upon TGF-β. To scale up a little piece of cartilage became a big challenge. Tuan prepared a three-dimen sional scaff old made out of nanofi bers by using electro spinning processes. He fi nally succeeded in getting cartilage pieces with diameters ranging from 1.5 to 4 cm. Next, Tuan's working group wanted to bring them into animals. Owing to the (now) big size of the cartilage pieces, big animals (for example, pigs) were needed. Th e aim of the following in vivo experiments was to repair iatrogenic cartilage defects. Tuan showed that nano fi brous scaff olds seeded with hMSCs eff ectively repaired cartilage defects in a swine model. Furthermore, Tuan proposed that, by regulating the stem cell niche, hMSCs should be able to diff erentiate into osteoblasts, chondro cytes, and adipocytes and thereby lead to the desired plasticity of the joint. In a search for genes downregulated in diff erentiated cells and upregulated in undiff erentiated cells, they found IL-6 as a candidate stemness gene to maintain the proliferative and undiff erentiated state of hMSC stemness, an important parameter for the optimization of manipulation of hMSCs.
Session 6: Updates in rheumatology
Chairs: Tsutomu Takeuchi, Tokyo, Japan, and Jesús Salvador, Madrid, Spain Session 6 summarized by Kerstin Klein Novel pain targets Hanns-Ulrich Zeilhofer, Zurich, Switzerland
In his talk, Hanns-Ulrich Zeilhofer presented three novel promising targets for the treatment of chronic pain: (a) the transient receptor potential cation channel subfamily V member 1 (TRPV1), (b) Na + channels (Nav1.7 and Nav1.8), and (c) the nerve growth factor (NGF). TRPV1 was originally identifi ed as a receptor for capsaicin, the main pungent ingredient in hot chili peppers. TRPV1 channels are activated upon noxious heat and mechanical damage. TRPV1 −/− mice were still responsive to noxious heat but were insensitive to infl ammatory hyperalgesia. Clinical studies for TRPV1 antagonists were promising. However, the main side eff ect in treated patients was hyperthermia. Na + channels are established targets for local analgetics and lately have also been in discussion as targets for the treatment of chronic pain. Th e SCN9A gene, encoding for Nav1.7, has been associated with diverse Na + channelopathies. An SCN9A mutation, prevalent in Pakistani families and leading to a premature stop codon, led to pain insensitivity of the aff ected individuals. Furthermore, gainof-function mutations of the SCN9A gene cause two diff erent diseases. In patients with erythro melalgia, Nav1.7 is activated at lower potentials, whereas in patients with paramyxal extreme pain disorder, Nav1.7 channel activation is extremely prolonged.
Another group of promising drugs for the treatment of chronic pain consists of antagonists of the neurotrophin NGF. NGF binding to its high-affi nity receptor tyrosine kinase receptor A (TrkA) in the dorsal root ganglion induces a signal cascade that results in the release of calcitonin gene-related peptide, substance P, and brainderived neurotrophic factor. Beside nerves, cells such as keratinocytes express NGF. During infl ammation, mast cells and macrophages serve as additional sources of NGF. Pfi zer Inc (New York, NY, USA) has developed a monoclonal antibody (tanezumab) against NGF. Clinical trials for the treatment of knee pain due to OA have been stopped recently. However, clinical trials for other pain conditions are ongoing. Since the treatment of large groups of patients with monoclonal antibodies is costly, a vaccination against NGF (NGF-Qβ) was developed in Zeilhofer's lab. Vaccinated mice in a model of infl am matory pain recovered faster than control animals. Furthermore, vaccination reduced thermal hyperalgesia in a mouse model of CIA. Side eff ects on peptidergic sensory nerve fi bers were not observed. Furthermore, no undesired eff ects concerning the inte grity of the bloodbrain barrier were found.
Better understanding the hidden face of osteoarthritis Jean-Pierre Pelletier, Montreal, QC, Canada
In his talk, Jean-Pierre Pelletier pointed out the necessity of the development of disease-modifying drugs for the treatment of OA (DMOADs). So far, no DMOADs have been approved by the US Food and Drug Administration, and current therapies for OA are directed toward control ling symptoms, maintaining function, and reducing further joint damage. A challenging issue in the development of DMOADs is the design of clinical trials. First of all, a careful selection of patients is important since age, gender, body mass index, and other factors have been reported to have an impact on study outcome. So far, no clear guidelines for inclusion criteria for patients exist. Other important aspects are the method of determination of disease progression and the selection of target joints. So far, the evaluation of symptoms in DMOAD trials is the same as in short-term trials. Pelletier suggested focusing on the global evaluation of structural changes in several joints instead of measuring a reduction of pain on the visual analogue scale. Furthermore, he recommended the use of quantitative magnetic resonance imaging (qMRI) instead of x-ray technology for the measurement of structural changes in the joints. In 2009, Raynauld and colleagues published the fi rst multicenter clinical trial study using qMRI (Raynauld JP et al., Ann Rheum Dis, 2009) . Pelletier advised the recording of total joint replacements after 6 years of follow-up; these data, which would serve as an adequate readout for DMOAD trials, can be easily collected by means of questionnaires. So far, no international guidelines for DMOAD clinical trials exist. Wesley Brooks pointed out the role of the loss of epigenetic control in the development of autoimmune diseases. Th e female predominance of diseases such as mul tiple sclerosis, RA, lupus erythematosus, and Sjörgren syndrome suggests the involvement of hormones, X chromosomes, and the X-chromosomal inactivation process. Early in embryogenesis, the second X chromosome in female cells undergoes inactivation in order to achieve dosage compensation. Approximately 85% of the genes on the inactivated X chromosome (Xi) undergo inactivation. Owing to its perinuclear localization, the late replication, hypermethylation, and the limited access for DNA repair, the Xi is especially vulnerable to DNA damage. DNA mutations could interfere with the X inactivation process and then could become reactivated in daughter cells, resulting in a loss of epigenetic control. An interesting region on the short arm of the X chromosome is Xp22.1, which encodes for enzymes involved in the polyamine synthesis (namely spermine synthase and spermine/spermidine N1-acetyltransferase). Many agents, including estrogens, UV light, and viral infections, can induce polyamine synthesis. Increased polyamine synthesis could impact chromatin methylation and epigenetic control because of the increased needs for S-adenosylmethionine, which is also used as a substrate for DNA methylation. Furthermore, polyamines can stabilize Z-DNA and alter gene transcription. Abnormal RNA polymerase III activity and overexpression of pseudogenes, such as Alu and LINE L1 sequences, have been described. Brooks suggested the enzymes ornithine decarboxylase and spermine/spermidine N1-acetyltransferase as suitable new targets for drug discovery.
Do regulatory T cells control the
ASIA: a new syndrome of autoimmune diseases induced by adjuvants Yehuda Shoenfeld, Tal-Hashomer, Israel
In his presentation, Yehuda Shoenfeld discussed an autoimmune disease called 'autoimmune syndrome induced by adjuvant' (ASIA). Autoimmune diseases have multifactorial causes, such as genetic predisposition, immunodefi ciency, hormones, and environmental factors, including adjuvants. Adjuvants, the foremost of which is aluminum, are widely used in vaccines to stimulate the immune system. Although Shoenfeld did not want to doubt the benefi cial eff ects of vaccines, he referred to numerous studies and case reports documenting that vaccination of naive subjects can lead to autoimmunity. Causal relationships between diphtheria-tetanus-pertussis vaccination and measles-mumps-rubella (MMR) vaccination with arthritis have been described. Furthermore, a link between MMR and autoimmune thrombocytopenia has been reported. Whereas early adverse events of vaccinations (for example, fever or local reactions at the site of injection) are easily documented, the major diffi culty of diagnosing ASIA is the lack of temporal association between the vaccination and the incidence of symptoms, and this lack is due to long latency periods. Moreover, the criteria for causality are not well defi ned, and unlike effi cacy, safety cannot be measured directly. Animal models can be useful for studying the interrelation between vaccination and autoimmune phenomena.
Some vaccinations use silicone as an adjuvant. Th e wide use of silicone in breast operations led to many symptomatic cases of autoimmune disease. In some cases, the removal of silicone was suffi cient for recovery of the patients. Shoenfeld concluded that the association between vaccination and autoimmunity raises many clinical, methodological, and ethical questions and that there is a need for increasing vaccine safety and identifying possible risk factors for the incidence of ASIA.
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